neurodegenerative diseases

View All

Pharma News for Eisai, Biogen, Merck, BMS, Kyverna
Eisai Submits Marketing Authorization Application for Tasurgratinib; CHMP Issues Positive Opinion for Biogen’s SKYCLARYS; European Commission Approves Merck’s KEYTRUDA + Chemotherapy HER2-ve Gastric or GEJ Adenocarcinoma; BMS Provides Update on RELATIVITY-123 Trial; Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101; Verrica and Torii Pharma Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208

Eisai Submits Marketing Authorization Application In Japan for Anticancer Agent Tasurgratinib For Biliary Tract Cancer With FGFR2 Gene Fusion Eisai Co., Ltd. has officially submitted a request for marketing authorization in Japan for tasurgratinib succinate, its internally developed tyrosine kinase inhibitor tar...

Find More

Creutzfeldt-Jakob disease (CJD)
‘Transmissible’ Alzheimer’s theory gains traction

Neuroscientists have garnered more evidence for the hypothesis regarding sticky proteins, which is a symbol of neurodegenerative diseases. This can be transferred between people under particular conditions and also cause new damage in a brain of recipient. Their research does not hint that disorders such as Alz...

Find More